MAPK1 and metastatic melanoma: In the absence of a clear biomarker that can determine which patients will benefit the most from each type of treatment [154], emerging evidence supports the idea of combining RAS–ERK pathway-targeted therapy and immune checkpoint inhibitors may be promising for the treatment of metastatic melanoma (Figure 3).